Latest News

STAT Plus: Roche partners with Arrakis Therapeutics to develop drugs that target RNA

Last year, Arrakis Therapeutics announced early but important progress toward a drug-development goal long thought to be a biotech fantasy: the creation of oral medicines that can target RNA, the messenger-like molecules that turn genetic instructions into proteins.

On Wednesday, the Waltham, Mass.-based startup checked another box on its list of milestones: signing on its first strategic partner, the Swiss pharma giant Roche, which will pay $190 million upfront to license Arrakis’ technology. The two companies will work together to develop a new class of pills with potential to block the RNA machinery that makes disease-causing proteins.

Continue to STAT Plus to read the full story…

Source link

Related posts

Waves of Malice: A Longitudinal Measurement of the Malicious File Delivery Ecosystem on the Web


Telemedicine has undergone a series of changes from #telemedicine systems which …


Reducing cellular proliferation could help deplete HIV reservoir and lead to a functional cure


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World